A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.
T: 020 3108 3280
Visavadia is the Departmental Administrator for UCL Enterprise. Deepa's
responsibilities include managing the finances, HR, administration and office
management of UCL Enterprise.
joined UCL in 1994 where she worked at the Development Planning Unit for 10
years and later moved on to Department of Medicine before transferring to UCL
Advances in February 2007. Before joining UCL, Deepa worked for the United
Nations Centre for Human Settlements (Habitat) in Nairobi, Kenya.